Patient disposition and baseline characteristics
DISEASE CHARACTERISTIC
Of the 420 patients randomized in the double-blind treatment period, 409 entered the open-label extension phase at week 14 (continuous upadacitinib: Patient disposition through week 52. Patient demographics and baseline disease characteristics have been reported previously [